Close Menu

NEW YORK – Quanterix said after the close of the market on Monday that it has entered into a licensing and supply agreement with Siemens Healthineers to provide that company access to neurofilament-light (Nf-L) antibodies.

Siemens will use the technology to develop blood-based Nf-L clinical tests. Financial and other terms of the deal were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.